The DOI matches its Crossref record; 25 of the 28 references it cites were found in a registry or an index.
Association of Histologic Disease Activity With Progression of Nonalcoholic Fatty Liver Disease
Open accessAbstract
Importance: The histologic evolution of the full spectrum of nonalcoholic fatty liver disease (NAFLD) and factors associated with progression or regression remain to be definitively established. Objective: To evaluate the histologic evolution of NAFLD and the factors associated with changes in disease severity over time. Design, Setting, and Participants: A prospective cohort substudy from the Nonalcoholic Steatohepatitis Clinical Research Network (NASH CRN) NAFLD Database study, a noninterventional registry, was performed at 8 university medical research centers. Masked assessment of liver histologic specimens was performed, using a prespecified protocol to score individual biopsies. Participants included 446 adults with NAFLD enrolled in the NASH CRN Database studies between October 27, 2004, and September 13, 2013, who underwent 2 liver biopsies 1 or more year apart. Data analysis was performed from October 2016 to October 2018. Main Outcomes and Measures: Progression and regression of fibrosis stage, using clinical, laboratory, and histologic findings, including the NAFLD activity score (NAS) (sum of scores for steatosis, lobular inflammation, and ballooning; range, 0-8, with 8 indicating more severe disease). Results: A total of 446 adults (mean [SD] age, 47 [11] years; 294 [65.9%] women) with NAFLD (NAFL, 86 [19.3%]), borderline NASH (84 [18.8%]), and definite NASH (276 [61.9%]) were studied. Over a mean (SD) interval of 4.9 (2.8) years between biopsies, NAFL resolved in 11 patients (12.8%) and progressed to steatohepatitis in 36 patients (41.9%). Steatohepatitis resolved in 24 (28.6%) of the patients with borderline NASH and 61 (22.1%) of those with definite NASH. Fibrosis progression or regression by at least 1 stage occurred in 132 (30%) and 151 [34%] participants, respectively. Metabolic syndrome (20 [95%] vs 108 [72%]; P = .03), baseline NAS (mean [SD], 5.0 [1.4] vs 4.3 [1.6]; P = .005), and smaller reduction in NAS (-0.2 [2] vs -0.9 [2]; P < .001) were associated with progression to advanced (stage 3-4) fibrosis vs those without progression to stage 3 to 4 fibrosis. Fibrosis regression was associated with lower baseline insulin level (20 vs 33 μU/mL; P = .02) and decrease in all NAS components (steatosis grade -0.8 [0.1] vs -0.3 [0.9]; P < .001; lobular inflammation -0.5 [0.8] vs -0.2 [0.9]; P < .001; ballooning -0.7 [1.1] vs -0.1 [0.9]; P < .001). Only baseline aspartate aminotransferase (AST) levels were associated with fibrosis regression vs no change and progression vs no change on multivariable regression: baseline AST (regression: conditional odds ratio [cOR], 0.6 per 10 U/L AST; 95% CI, 0.4-0.7; P < .001; progression: cOR, 1.3; 95% CI, 1.1-1.5; P = .002). Changes in the AST level, alanine aminotransferase (ALT) level, and NAS were also associated with fibrosis regression and progression (ΔAST level: regression, cOR, 0.9; 95% CI, 0.6-1.2; P = .47; progression, cOR, 1.3; 95% CI, 1.0-1.6; P = .02; ΔALT level: regression, cOR, 0.7 per 10 U/L AST; 95% CI, 0.5-0.9; P = .002; progression, cOR, 1.0 per 10 U/L AST; 95% CI, 0.9-1.2; P = .93; ΔNAS: regression, cOR, 0.7; 95% CI, 0.6-0.9; P = .001; progression, cOR, 1.3; 95% CI, 1.1-1.5; P = .01). Conclusions and Relevance: Improvement or worsening of disease activity may be associated with fibrosis regression or progression, respectively, in NAFLD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In a natural history cohort of 445 individuals with 4.9 years mean follow-up between paired liver biopsies from the NASH CRN, improvement in the NAS over time was associated with fi brosis regression, and worsening of the NAS was associated with fi brosis progression. 260”
From EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD). (2024) · cites this paper as [260]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Several studies have shown that changes in histologically assessed activity are linked with changes in fi brosis over time.”
From EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD). (2024) · cites this paper as [260]
The cited source says what the claim attributes to it.
In the citing paper
“In a natural history cohort of 445 individuals with 4.9 years mean follow-up between paired liver biopsies from the NASH CRN, improvement in the NAS over time was associated with fi brosis regression, and worsening of the NAS was associated with fi brosis progression. 260”
From EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD). (2024) · cites this paper as [260]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A new look at the statistical model identification
Akaike, H. (1974) · IEEE Transactions on Automatic Control · doi:10.1109/tac.1974.1100705 · Cited by 51,879
SAUNDERS, J. B., AASLAND, O. G., BABOR, T. F., DE LA FUENTE, J. R., & GRANT, M. (1993) · Addiction · doi:10.1111/j.1360-0443.1993.tb02093.x · Cited by 13,597 · cited 3×
“Individuals whose biopsies demonstrated definite NASH, compared with those with NAFL, were older (mean [SD], 49 [11] vs 45 [11] years; P = .”
BackgroundInfluentialDesign and validation of a histological scoring system for nonalcoholic fatty liver disease†
Kleiner, D. E., Brunt, E. M., Van Natta, M., Behling, C., Contos, M. J., Cummings, O. W., Ferrell, L. D., Liu, Y., Torbenson, M. S., Unalp‐Arida, A., et al. (2005) · Hepatology · doi:10.1002/hep.20701 · Cited by 10,791
Self-citationChalasani, N., Younossi, Z., Lavine, J. E., Charlton, M., Cusi, K., Rinella, M., Harrison, S. A., Brunt, E. M., & Sanyal, A. J. (2018) · Hepatology · doi:10.1002/hep.29367 · Cited by 7,239
Self-citationPioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis
Sanyal, A. J., Chalasani, N., Kowdley, K. V., McCullough, A., Diehl, A. M., Bass, N. M., Neuschwander-Tetri, B. A., Lavine, J. E., Tonascia, J., Unalp, A., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0907929 · Cited by 3,327
Self-citationAngulo, P., Kleiner, D. E., Dam-Larsen, S., Adams, L. A., Bjornsson, E. S., Charatcharoenwitthaya, P., Mills, P. R., Keach, J. C., Lafferty, H. D., Stahler, A., et al. (2015) · Gastroenterology · doi:10.1053/j.gastro.2015.04.043 · Cited by 2,987
Self-citationThe Natural History of Nonalcoholic Fatty Liver Disease: A Population-Based Cohort Study
Adams, L. A., Lymp, J. F., St. Sauver, J., Sanderson, S. O., Lindor, K. D., Feldstein, A., & Angulo, P. (2005) · Gastroenterology · doi:10.1053/j.gastro.2005.04.014 · Cited by 2,890
Vilar-Gomez, E., Martinez-Perez, Y., Calzadilla-Bertot, L., Torres-Gonzalez, A., Gra-Oramas, B., Gonzalez-Fabian, L., Friedman, S. L., Diago, M., & Romero-Gomez, M. (2015) · Gastroenterology · doi:10.1053/j.gastro.2015.04.005 · Cited by 2,492
Long-term follow-up of patients with NAFLD and elevated liver enzymes
Ekstedt, M., Franzén, L. E., Mathiesen, U. L., Thorelius, L., Holmqvist, M., Bodemar, G., & Kechagias, S. (2006) · Hepatology · doi:10.1002/hep.21327 · Cited by 2,302
Singh, S., Allen, A. M., Wang, Z., Prokop, L. J., Murad, M. H., & Loomba, R. (2015) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2014.04.014 · Cited by 1,748
Self-citation
Flagged first, then by citations
3 of the 28 references couldn’t be matched to a known paper.
Cited by
Sorted by citations
Items 201–300 of 372
Veroli, B. D., Bentanachs, R., Roglans, N., Alegret, M., Giona, L., Profumo, E., Berry, A., Saso, L., Laguna, J. C., & Buttari, B. (2024) · Cells · doi:10.3390/cells13151247 · Cited by 17
Kawanaka, M., Kamada, Y., Takahashi, K., Iwaki, M., Nishino, K., Zhao, W., Seko, Y., Yoneda, M., Kubotsu, Y., Fujii, H., et al. (2024) · Gastro Hep Advances · doi:10.1016/j.gastha.2024.08.008 · Cited by 14
Role of Liver Biopsy in Clinical Trials and Clinical Management of Nonalcoholic Fatty Liver Disease
Goodman, Z. D. (2023) · Clinics in Liver Disease · doi:10.1016/j.cld.2023.01.017 · Cited by 13
Noninvasive Tests Used in Risk Stratification of Patients with Nonalcoholic Fatty Liver Disease
Henry, L. L., Eberly, K. E., Shah, D., Kumar, A. R., & Younossi, Z. M. (2023) · Clinics in Liver Disease · doi:10.1016/j.cld.2023.01.022 · Cited by 13
Zhu, L., Liu, C., Li, Z.-R., Niu, C., & Wu, J. (2021) · Laboratory Investigation · doi:10.1038/s41374-021-00535-3 · Cited by 13
Adams, L. A., Kemp, W. W., Muller, K., Powell, E. E., Roberts, S. K., Bertot, L. C., Best, S., Deed, G., Emery, J. D., HOCKING, S. L., et al. (2025) · The Medical Journal of Australia · doi:10.5694/mja2.70008 · Cited by 12
El-Azab, G., Elkhouly, E., Abouyoussef, R. A. M., & Nagdy, H. M. (2025) · Clinical and Experimental Medicine · doi:10.1007/s10238-025-01922-6 · Cited by 12
Friedman, S. L., & Sanyal, A. J. (2023) · Hepatology · doi:10.1097/hep.0000000000000389 · Cited by 12
Self-citationWang, X., Jin, R., Li, X., Yang, Q., Teng, X., Liu, F., Wu, N., Rao, H., & Liu, F. (2023) · Frontiers in Medicine · doi:10.3389/fmed.2023.1172058 · Cited by 12
Harrison, S. A., Dubourg, J., Knott, M., & Colca, J. R. (2023) · Hepatology · doi:10.1097/hep.0000000000000710 · Cited by 13
Yuan, H., Tong, X., Ren, Y., Li, Y., Wang, X., Chen, L., Chen, S., Jin, X., Wang, X., Targher, G., et al. (2024) · Liver International · doi:10.1111/liv.16025 · Cited by 12
Self-citationOrgan damage proteomic signature identifies patients with MASLD at risk of systemic complications
Pirola, C. J., Diambra, L. A., Gianotti, T. F., Castaño, G. O., Martino, J. S., Garaycoechea, M. E., & Sookoian, S. C. (2025) · Hepatology · doi:10.1097/hep.0000000000001346 · Cited by 13
Sabotta, C. M., Kwan, S., Petty, L. E., Below, J. E., Joon, A. Y., Wei, P., Fisher‐Hoch, S. P., McCormick, J. B., & Beretta, L. (2022) · Frontiers in Genetics · doi:10.3389/fgene.2022.995488 · Cited by 12
Future Treatment Options and Regimens for Nonalcoholic Fatty Liver Disease
Francque, S., & Ratziu, V. (2023) · Clinics in Liver Disease · doi:10.1016/j.cld.2023.01.010 · Cited by 12
Han, X., Zhang, X., Liu, Z., Fan, H., Guo, C., Wang, H., Gu, Y., & Zhang, T. (2024) · Journal of Diabetes · doi:10.1111/1753-0407.13564 · Cited by 11
Suppressing MASH fibrotic progression by blocking succinate-GPR91 signaling in HSCs
Xie, L., Chen, H., Zhang, L., Yang, Y., Zhou, Y., Ma, Y., Liu, C., Wang, Y.-L., Zhu, Q., Yan, Y.-J., et al. (2025) · Hepatology · doi:10.1097/hep.0000000000001405 · Cited by 11
Lim, A. S., Cruz, S. N., Uddin, A. A., Malysheva, O., Caudill, M. A., Alonso, C., Montilla, A., Karsdal, M. A., Leeming, D. J., Mayorca‐Guiliani, A. E., et al. (2025) · Hepatology · doi:10.1097/hep.0000000000001477 · Cited by 11
Henderson, G. C., & Meyer, J. M. (2021) · Journal of Applied Physiology · doi:10.1152/japplphysiol.00930.2020 · Cited by 11
Evolução da doença hepática gordurosa não alcoólica: revisão de literatura
Miquelito, J. T., & de Siqueira, E. C. (2022) · Revista de Saúde · doi:10.21727/rs.v13i1.2915 · Cited by 11
Potter, K. J., Phinney, J., Kulai, T. B., & Munro, V. (2025) · Journal of the Canadian Association of Gastroenterology · doi:10.1093/jcag/gwae057 · Cited by 13
The Liver in Diabetes and Metabolic Syndrome
Mahmoud, M. C., & Abdelmalek, M. F. (2025) · Clinics in Liver Disease · doi:10.1016/j.cld.2025.04.003 · Cited by 14
Expression of Notch family is altered in non‑alcoholic fatty liver disease
Ding, W., Wu, W., Chen, Y., Chen, H., Fan, J., & Qiao, L. (2020) · Molecular Medicine Reports · doi:10.3892/mmr.2020.11249 · Cited by 11
García‐Cortés, M., Toro-Ortiz, J. P., & García-García, A. (2023) · Exploration of Digestive Diseases · doi:10.37349/edd.2023.00034 · Cited by 10
Naoumov, N. V., Kleiner, D. E., Chng, E., Brees, D., Saravanan, C., Ren, Y., Tai, D., & Sanyal, A. J. (2024) · Liver International · doi:10.1111/liv.16092 · Cited by 11
Self-citationSuwa, K., Yamaguchi, T., Yoshida, K., Murata, M., Ichimura‐Shimizu, M., Tsuneyama, K., Seki, T., & Okazaki, K. (2020) · Cancers · doi:10.3390/cancers12020286 · Cited by 10
Zou, C., Sun, Y., & Liang, J. (2022) · Clinics and Research in Hepatology and Gastroenterology · doi:10.1016/j.clinre.2022.102053 · Cited by 11
Nonalcoholic fatty liver disease: use of diagnostic biomarkers and modalities in clinical practice
Alqahtani, S. A., & Schattenberg, J. M. (2021) · Expert Review of Molecular Diagnostics · doi:10.1080/14737159.2021.1964958 · Cited by 10
Jiao, B., Wang, B., Liu, B., Zhao, J., & Zhang, Y. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1468476 · Cited by 9
Choi, Y. J., Park, J.-H., Cho, H.-I., Shin, M., & Nah, E. (2025) · Metabolites · doi:10.3390/metabo15050299 · Cited by 10
Metabolic drivers of MASLD and MASH: from hormonal imbalance to fibrosis
Gastaldelli, A., Scoditti, E., & Macedo, M. P. (2026) · Diabetologia · doi:10.1007/s00125-026-06774-7 · Cited by 11
Steatosis, Steatohepatitis and Cancer Immunotherapy: An Intricate Story
Cataldi, M., Manco, F., & Tarantino, G. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222312947 · Cited by 9
Mechanism of CD38 via NAD + in the Development of Non-alcoholic Fatty Liver Disease
Dong, M., Wang, S., & Pei, Z. (2023) · International Journal of Medical Sciences · doi:10.7150/ijms.81381 · Cited by 9
Metabolic and Risk Profiles of Lean and Non-Lean Hepatic Steatosis among US Adults
Li, M., Zhang, W., Li, X., Liang, S., Zhang, Y., Mo, Y., Rao, S., Zhang, H., Huang, Y. C., Zhu, Y., et al. (2023) · Nutrients · doi:10.3390/nu15132856 · Cited by 9
Emerging concepts in the detection of liver fibrosis in non-alcoholic fatty liver disease
Armandi, A., Michel, M. S., Gjini, K., Emrich, T., Bugianesi, E., & Schattenberg, J. M. (2023) · Expert Review of Molecular Diagnostics · doi:10.1080/14737159.2023.2242779 · Cited by 9
Shinde, S., Nelson, D. R., Mitroi, J., Heaton, P. C., Hincapie, A. L., & Brouwers, B. (2023) · Current Medical Research and Opinion · doi:10.1080/03007995.2023.2279676 · Cited by 11
The diagnostic conundrum in non-alcoholic fatty liver disease
Rosato, V., Masarone, M., Aglitti, A., & Persico, M. (2020) · Exploration of Medicine · doi:10.37349/emed.2020.00018 · Cited by 9
Wan, Q., Peng, H., Lyu, J., Liu, F., Cheng, C., Qiao, Y., Deng, J., Zheng, H., Wang, Y., Zou, C., et al. (2022) · Journal of Magnetic Resonance Imaging · doi:10.1002/jmri.28131 · Cited by 9
Truong, E., Alnimer, L., GORNBEIN, J. A., Yang, J. D., Alkhouri, N., Harrison, S. A., & Noureddin, M. (2025) · Digestive Diseases and Sciences · doi:10.1007/s10620-025-08850-1 · Cited by 9
Le, P., Tatar, M., Rothberg, M. B., Wilson, L., Allende, D. S., Diehl, A. M., Loomba, R. S., Chalasani, N., Neuschwander‐Tetri, B. A., Kowdley, K. V., et al. (2025) · The American Journal of Gastroenterology · doi:10.14309/ajg.0000000000003455 · Cited by 8
Self-citationHashim, M. M. A., Khan, M. A. M., Ashraf, M. U., Mohsin, S., Zahoor, K., Niazi, J., Khan, A., Muzaffar, S., Makhdumi, M., Ibad, O. A., et al. (2025) · Cureus · doi:10.7759/cureus.86963 · Cited by 8
Is FIB-4 the right tool for screening for liver fibrosis?
Heyens, L. J. M., Malde, D. P. A. V., Us, G. D., Innocenti, F., Struyve, M., Steenkiste, C. V., Francque, S., Robaeys, G., Koek, G. H., Kockaerts, Y., et al. (2025) · Annals of Hepatology · doi:10.1016/j.aohep.2025.102176 · Cited by 9
Diao, Y., Hu, D., Hu, X., Wang, P., Wang, X., Luo, X., Wang, H., & Ning, Q. (2022) · Infectious Diseases and Therapy · doi:10.1007/s40121-022-00629-5 · Cited by 8
Esparza, J., Shrestha, U., Kleiner, D. E., Crawford, J. M., Vanatta, J. M., Satapathy, S. K., & Tipirneni‐Sajja, A. (2022) · Journal of Clinical and Experimental Hepatology · doi:10.1016/j.jceh.2022.12.003 · Cited by 8
Self-citationThe effect of hepatic steatosis on 18F-FDG uptake in PET-CT examinations of cancer Egyptian patients
Ali, M. A., El-Abd, E. A., Morsi, M. I., Safwany, M. M. E., & El-Sayed, M. Z. (2023) · European Journal of Hybrid Imaging · doi:10.1186/s41824-023-00173-6 · Cited by 8
Pellicori, P., Vaduganathan, M., Ferreira, J. P., Zannad, F. M., & Sanyal, A. J. (2021) · Diabetes & Metabolism · doi:10.1016/j.diabet.2021.101281 · Cited by 8
Self-citationDunn, W., Castéra, L., & Loomba, R. S. (2023) · Clinics in Liver Disease · doi:10.1016/j.cld.2023.01.020 · Cited by 8
Self-citationKhalfallah, M., Doblas, S., Hammoutène, A., Juléa, F., Postic, C., Valla, D. C., Paradis, V., Garteiser, P., & BEERS, B. E. V. (2023) · Journal of Magnetic Resonance Imaging · doi:10.1002/jmri.28765 · Cited by 8
Han, M., Jeong, S., Song, J., Park, S. J., Lee, K., Lee, K., & Park, S. M. (2023) · Tobacco Induced Diseases · doi:10.18332/tid/159167 · Cited by 7
TINIAKOS, D. G., Anstee, Q. M., Brunt, E. M., & Burt, A. D. (2023) · Elsevier eBooks · doi:10.1016/b978-0-7020-8228-3.00005-3 · Cited by 7
Self-citationRigor, J., MARTINS, M. E., Passos, B., Oliveira, R., & Martins‐Mendes, D. (2024) · Minerva Medica · doi:10.23736/s0026-4806.24.09290-5 · Cited by 7
Li, L., Sun, Y., Li, L., Zheng, W., Zha, W., Zhao, T., Zhu, G., & Li, H. (2024) · FEBS Journal · doi:10.1111/febs.17299 · Cited by 7
Deep phenotyping of patients with MASLD upon high-intensity interval training
Houttu, V., Boulund, U., Troelstra, M., Csader, S., Stols‐Gonçalves, D., Mak, A. L., van Dijk, A., Bouts, J., Winkelmeijer, M., Verdoes, X., et al. (2024) · JHEP Reports · doi:10.1016/j.jhepr.2024.101289 · Cited by 8
Yu, L., Bao, S., Zhu, F., Xu, Y., Zu, F., Liu, Y., Jiang, R., Chen, S., & Chen, W. (2025) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s492153 · Cited by 7
Rodriguez, N. S., & Hartmann, P. (2025) · Pharmacological Reviews · doi:10.1016/j.pharmr.2025.100058 · Cited by 10
Austrian multisociety consensus on metabolic dysfunction-associated steatotic liver disease
Mandorfer, M., Semmler, G., Aigner, E. S., Bräuer, A., Brix, J. M., Clodi, M., Datz, C., Effenberger, M., Felsenreich, D. M., Ludvik, B. H., et al. (2025) · Wiener klinische Wochenschrift · doi:10.1007/s00508-025-02617-4 · Cited by 7
The Burden of Nonalcoholic Steatohepatitis: A Systematic Review of Epidemiology Studies
Tapper, E. B., Fleming, C., Rendon, A., Fernandes, J. D. D. R., Johansen, P., Augusto, M., & Nair, S. (2022) · Gastro Hep Advances · doi:10.1016/j.gastha.2022.06.016 · Cited by 7
Kado, A., Tsutsumi, T., Yotsuyanagi, H., Ikeuchi, K., Okushin, K., Moriya, K., Koike, K., & Fujishiro, M. (2023) · Journal of Gastroenterology · doi:10.1007/s00535-023-02038-y · Cited by 7
Reversal of nonalcoholic fatty liver disease reduces the risk of cardiovascular disease among Korean
Oh, Y. H., Jeong, S., Park, S. J., Ahn, J. C., & Park, S. M. (2023) · Medicine · doi:10.1097/md.0000000000035804 · Cited by 7
Jin, L., Gu, J., Zhang, Z., Du, C.-F., Xu, F., Huang, X., Gao, Z., Li, Y., Yu, L.-L., Zhang, X., et al. (2024) · Obesity Surgery · doi:10.1007/s11695-024-07139-y · Cited by 7
Sherman, M. S., Challa, P. K., Przybyszewski, E. M., Wilechansky, R. M., Uche-Anya, E. N., Ott, A. T., McGoldrick, J., Goessling, W., Khalili, H., & Simon, T. G. (2024) · Hepatology Communications · doi:10.1097/hc9.0000000000000403 · Cited by 7
Bohra, V., Tam, N. F. Y., Chen, L., Lai, K. K.-Y., Lam, W., Xu, S. J., Zhou, H., Lang, T., Lee, C.-L., & Lee, F. W. F. (2024) · Journal of Marine Science and Engineering · doi:10.3390/jmse12050802 · Cited by 7
Paediatric non-alcoholic fatty liver disease: an approach to pathological evaluation
Wang, C., Pai, A. K., & Putra, J. (2022) · Journal of Clinical Pathology · doi:10.1136/jclinpath-2022-208246 · Cited by 7
Meyer, E. L., Mesenbrink, P. G., Prospero, N. A. D., Pericàs, J. M., Glimm, E., Ratziu, V., Sena, E., König, F., & on behalf of the EU-PEARL NASH Investigators (2023) · PLoS ONE · doi:10.1371/journal.pone.0281674 · Cited by 7
Kado, A., Tsutsumi, T., Yotsuyanagi, H., Ikeuchi, K., Okushin, K., Moriya, K., Koike, K., & Fujishiro, M. (2023) · Hepatology Research · doi:10.1111/hepr.14009 · Cited by 7
Evaluating Pediatric NAFLD with Controlled Attenuation Parameter: A Comprehensive Narrative Review
Arteaga, Í., Chacón, C., Martínez-Escudé, A., Ruiz-Rojano, I., Diez-Fadrique, G., Carmona-Cervelló, M., & Torán‐Monserrat, P. (2025) · Diagnostics · doi:10.3390/diagnostics15030299 · Cited by 7
Pebriana, R. B., Chen, T., Derks, R. J. E., Blomberg, N., Grefhorst, A., Mohammed, Y., Nieuwdorp, M., Verheij, J., Doukas, M., Rensen, P. C. N., et al. (2025) · Journal of Lipid Research · doi:10.1016/j.jlr.2025.100845 · Cited by 6
Barrett, R., Archer, A. J., Cathcart, J., Abeysekera, K. W. M., Dillon, J. F., & Brennan, P. (2026) · Liver International · doi:10.1111/liv.70511 · Cited by 6
Current and experimental pharmacotherapy for the management of non-alcoholic fatty liver disease
Katsarou, A., Tsioulos, G., Kassi, E. N., & Chatzigeorgiou, A. (2024) · HORMONES · doi:10.1007/s42000-024-00588-1 · Cited by 8
Ultrasound radiomics-based logistic regression model for fibrotic NASH
Xia, F., Wei, W., Wang, J., Wang, Y., Wang, K., Zhang, C., & Zhu, Q. (2025) · BMC Gastroenterology · doi:10.1186/s12876-025-03605-8 · Cited by 6
Hígado graso (parte 1): aspectos generales, epidemiología, fisiopatología e historia natural
Ortíz, J. E. P., Luque, C. B. S., & Quiróz, R. J. O. (2022) · Revista Colombiana de Gastroenterología · doi:10.22516/25007440.952 · Cited by 9
Sharma, S., Choudhury, A. K., Thadikemalla, V. S. G., Rastogi, A., Gandhi, T. K., & Sarin, S. K. (2025) · Journal of Clinical and Experimental Hepatology · doi:10.1016/j.jceh.2025.103438 · Cited by 5
Huneault, H. E., Tiwari, P., Jarrell, Z. R., Smith, M. R., Chen, C.-Y., Tovar, A. R., Sanchez-Torres, C., Gillespie, S. E., Bai, S., Carrillo-Larco, R. M., et al. (2026) · Nature Communications · doi:10.1038/s41467-026-69735-z · Cited by 5
Self-citationHow Hepatologists Use Liver Biopsy in the Evaluation of Liver Disease?
Mitten, E. K., & Rutherford, A. (2023) · Surgical pathology clinics · doi:10.1016/j.path.2023.04.001 · Cited by 5
Pais, R., Chouik, Y., Moga, L., Lebedel, L., Silvain, C., Genser, L., Weill, D., Larrue, H., Malézieux, E., Jézequel, C., et al. (2024) · Obesity Surgery · doi:10.1007/s11695-024-07583-w · Cited by 5
Challenges in Histological Endpoints for MASH Therapies: An Exercise in Statistical Modelling
Shah, A., MacConell, L., Liberman, A., Bisceglie, A. M. D., & Shapiro, D. (2025) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.70023 · Cited by 5
Identification of Key Biomarkers and Immune Infiltration in Liver Tissue after Bariatric Surgery
Zhang, X., Li, J., Liu, T., Zhao, M., Liang, B., Chen, H., & Zhang, Z. (2022) · Disease Markers · doi:10.1155/2022/4369329 · Cited by 5
RetractedStéatose hépatique non alcoolique : diagnostic et traitement en 2022
Tagkou, N. M., & Goossens, N. (2023) · Schweizer Gastroenterologie · doi:10.1007/s43472-023-00091-9 · Cited by 8
Zeng, M., Chen, L., Li, Y., Mi, Y., & Xu, L. (2023) · Infectious Diseases & Immunity · doi:10.1097/id9.0000000000000085 · Cited by 5
Practical Guide, Challenges, and Pitfalls in Liver Fibrosis Staging
Matsukuma, K. E., & Yeh, M. M. (2023) · Surgical pathology clinics · doi:10.1016/j.path.2023.04.002 · Cited by 5
Self-citationKulkarni, S., Naz, N., Gu, H., Stoll, J. M., Thompson, M. D., & DeBosch, B. J. (2021) · Clinical Obesity · doi:10.1111/cob.12472 · Cited by 5
Nonalcoholic fatty liver disease
Siddiqui, M. S., & Sanyal, A. J. (2022) · Yamada's Textbook of Gastroenterology · doi:10.1002/9781119600206.ch96 · Cited by 5
Self-citationCurrently Approved and Future Regimens for Metabolic Dysfunction-Associated Steatohepatitis
Abreu, E. S., Noureddin, M., Takahashi, H., Schattenberg, J. M., & Abdelmalek, M. F. (2026) · Clinics in Liver Disease · doi:10.1016/j.cld.2026.01.004 · Cited by 4
Jacobson, I. M., Wong, V. W., Castéra, L., Anstee, Q. M., Noureddin, M., Cusi, K. J., Harrison, S. A., Bugianesi, E., & Younossi, Z. M. (2022) · Journal of Clinical Gastroenterology · doi:10.1097/mcg.0000000000001780 · Cited by 4
Jayabalan, D., Dhakal, S., Chandra, J., Fasser, D. A., Jeffrey, G. P., Garas, G., Vilar-Gomez, E., Calzadilla-Bertot, L., & Adams, L. A. (2026) · American Journal of Gastroenterology · doi:10.14309/ajg.0000000000003918 · Cited by 3
Kaya, E., Yilmaz, Y., & Alkhouri, N. (2025) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2025.2566258 · Cited by 5
Xiao, Z., Li, X., Gong, J., & Zhou, F. (2025) · European journal of medical research · doi:10.1186/s40001-025-03445-y · Cited by 3
Fructose-induced hepatic steatosis in non-obese children: A comprehensive review
Morscher, E., Furlano, R. I., & Légeret, C. (2026) · Nutrition and Health · doi:10.1177/02601060261430208 · Cited by 3
Lin, H., Qiu, S., Yang, Y., Yang, C., Shen, Z., Chen, Y., Zhang, Z., Feng, Y., & Yan, F. (2023) · Magnetic Resonance Imaging · doi:10.1016/j.mri.2023.07.017 · Cited by 3
Guarino, G., Strollo, F., Corte, T. D., Satta, E., & Gentile, S. (2023) · Diabetes Therapy · doi:10.1007/s13300-023-01478-2 · Cited by 3
Li, L., Liao, B., Cai, H., Zhang, Y., Deng, K., Chen, Y., Chen, M., Zhou, X., Tang, M., Dong, Z., et al. (2023) · Quantitative Imaging in Medicine and Surgery · doi:10.21037/qims-23-782 · Cited by 3
Chen, L.-Z., Jing, X., Chen, X., Xie, Y., Chen, Y., & Cai, X. (2024) · Reviews in Cardiovascular Medicine · doi:10.31083/j.rcm2509344 · Cited by 3
Non-Alcoholic Steatohepatitis Decreases Microsomal Liver Function in the Absence of Fibrosis
Verlinden, W., Mieghem, E. V., Depauw, L., Vanwolleghem, T., Vonghia, L., Weyler, J., Driessen, A. L. C., Callens, D., Roosens, L., Dirinck, E. L., et al. (2020) · Biomedicines · doi:10.3390/biomedicines8120546 · Cited by 3
Prospects for a better diagnosis and prognosis of NAFLD: a pathologist´s view
Lackner, C. (2021) · Hepatoma Research · doi:10.20517/2394-5079.2020.137 · Cited by 3
Biomarkers for Liver Fibrosis Post–Liver Transplantation: Not As Easy As It Looks
Francque, S. (2020) · Liver Transplantation · doi:10.1002/lt.25927 · Cited by 3
Chung, S. W., Park, M. K., Zhang, X., Wang, T., Jemielita, T., Fernandes, G. F., Engel, S. S., Jang, H., Lee, Y. B., Cho, E. J., et al. (2024) · Canadian Journal of Gastroenterology and Hepatology · doi:10.1155/2024/5667986 · Cited by 2
Saarinen, K., Färkkilä, M. A., Jula, A., Erlund, I., Vihervaara, T., Lundqvist, A., & Åberg, F. O. (2025) · Scandinavian Journal of Gastroenterology · doi:10.1080/00365521.2025.2454247 · Cited by 2
A Perfect MASH Comparing Resmetirom and GLP-1 Agonists for Metabolic-Associated Steatohepatitis
Lin, J., Green, V., Sohal, A., & Roytman, M. M. (2025) · Journal of Clinical Gastroenterology · doi:10.1097/mcg.0000000000002234 · Cited by 3
Li, C., Wang, H., Liu, L., Liu, C., Wang, Y.-Y., Yin, L., Yang, Y.-L., Tian, S., Qian, J., Zhou, M., et al. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c02078 · Cited by 2
Role of ChREBP–PPARα–FGF21 Axis in Metabolic Dysfunction of MASLD
Girón, K. M. P., Nazará, Z., Maldonado‐González, M., Martínez‐López, E., Sánchez-Muñoz, M. P., Bautista-López, C. A., Aldana-Aguiñaga, M. S., Domínguez-Rosales, J. A., Vargas‐Guerrero, B., & Ruiz‐Madrigal, B. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms262311425 · Cited by 3
Xu, Z., Zhu, Y., Chen, F., Fan, Q.-Y., Wang, R., Fu, Y., Wu, X., Zhu, L., Ha, F., Ye, Q., et al. (2025) · Liver International · doi:10.1111/liv.70491 · Cited by 4
Metadata
- Authors
- Kleiner, D. E., Brunt, E. M., Wilson, L. A., Behling, C., Guy, C., Contos, M., Cummings, O., Yeh, M., Gill, R., Chalasani, N., Neuschwander-Tetri, B. A., Diehl, A. M., Dasarathy, S., Terrault, N., Kowdley, K., Loomba, R., Belt, P., Tonascia, J., Lavine, J. E., Sanyal, A. J., & for the Nonalcoholic Steatohepatitis Clinical Research Network
- Affiliations
- National Institutes of Health (US)
- Washington University in St. Louis (US)
- Johns Hopkins University (US)
- University of California San Diego (US)
- Duke University (US)
- Virginia Commonwealth University (US)
- Indiana University School of Medicine (US)
- University of Washington (US)
- University of California, San Francisco (US)
- Indiana University Indianapolis (US)
- Division of Gastroenterology, Saint Louis University School of Medicine, St Louis, Missouri
- Cleveland Clinic (US)
- University of Southern California (US)
- Swedish Medical Center (US)
- Columbia University Irving Medical Center (US)
- Corresponding author
- Kleiner, David E.
- Sanyal, Arun J.
- ORCID
- Venue
- JAMA Network Open
- Publisher
- American Medical Association (AMA)
- Published
- 2019-10-04
- Volume
- 2
- Issue
- 10
- Pages
- e1912565
- ISSN
- 2574-3805 (ISSN-L)
- PMC
- PMC6784786
- OpenAlex
- W2977362851
- Cited by
- 372
- References
- 28
- Citations by year
- 2026: 32 · 2025: 53 · 2024: 48 · 2023: 66 · 2022: 62 · 2021: 65 · 2020: 44 · 2019: 2
- FWCI
- 32.92
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- Locations
- JAMA Network Open (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Digital Commons@Becker (Washington University School of Medicine) (submittedVersion, cc-by)
- IUScholarWorks (Indiana University) (submittedVersion, cc-by)
- Purdue University Indianapolis (Indiana University) (submittedVersion, cc-by)
- Funders
- National Institutes of Health (UL1TR000100, UL1TR000423, UL1TR000436, UL1TR000058, UL1TR000004, UL1TR000448, UL1TR000006, UL1TR000439, UL1TR002548, UL1TR001442, UL1TR002345, UL1TR002319)
- National Institute of Diabetes and Digestive and Kidney Diseases (U01DK061730, U01DK061731, U01DK061713, U24DK061730, U01DK061728, U01DK061737, U01DK061732, U01DK061734, U01DK061718, U01DK061738)
- National Center for Advancing Translational Sciences
- Topics
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Health Sciences › Medicine › Hepatology › Liver Diseases and Immunity
- Health Sciences › Medicine › Hepatology › Liver physiology and pathology
- Keywords
- non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, disease progression, fibrosis regression, NAFLD activity score, metabolic syndrome, steatosis, lobular inflammation, ballooning, liver biopsy
- MeSH terms
- Academic Medical Centers, Adult, Aspartate Aminotransferases, Female, Humans, Liver, Liver Cirrhosis, Male, Middle Aged, Risk Factors, United States, Cohort Studies, Weight Gain, Disease Progression, Non-alcoholic Fatty Liver Disease
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
